

# PART I: INTERNATIONAL HEMATOLOGIC ONCOLOGY TUMOR BOARD

## Practical Perspectives on Current Challenging Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

### Select Publications

#### ZELENETZ

- Boehme V et al. **CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).** *Blood* 2009;113(17):3896-902.
- Feugier P et al. **Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte.** *J Clin Oncol* 2005;23(18):4117.
- Gholam D et al. **Primary breast lymphoma.** *Leuk Lymph* 2003;44:1173-8.
- Jeanneret-Sozzi W et al. **Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicenter Rare Cancer Network study.** *BMC Cancer* 2008;8:86.
- Ryan GF et al. **Primary non-Hodgkin's lymphoma of the breast: Retrospective analysis of prognosis and patterns of failure in two Australian centers.** *Clin Lymph Myeloma* 2006;6(4):337-41.
- Tai WM et al. **Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- and post-rituximab.** *Ann Hematol* 2011;90(7):809-18.
- Tomita Y et al. **A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.** *Cancer Sci* 2011;102(4):697-705.
- Villa D et al. **Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy.** *Ann Oncol* 2010;21(5):1046-52.
- Yamamoto W et al. **Central nervous system involvement in diffuse large B-cell lymphoma.** *Eur J Hematol* 2010;85(1):6-10.
- Yhim HY et al. **Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.** *Int J Cancer* 2011;[Epub ahead of print].

#### GREGORY

- Ardeshtna KM et al. **An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with Stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis.** *Proc ASH* 2010;Abstract 6.
- Colt JS et al. **Residential insecticide use and risk of non-Hodgkin's lymphoma.** *Cancer Epidemiol Biomarkers Prev* 2006;15(2):251-7.
- Fowler NH et al. **Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.** *Proc ASCO* 2009;Abstract 8548.
- Friedberg JW et al. **Follicular lymphoma in the United States: First report of the national LymphoCare study.** *J Clin Oncol* 2009;27(8):1202-8.
- Hardell L, Eriksson M. **A case-control study of non-Hodgkin lymphoma and exposure to pesticides.** *Cancer* 1999;85(6):1353-60.
- Kahl BS et al. **Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma.** *Proc ASH* 2011;Abstract LBA-6.

McDuffie HH et al. **Non-Hodgkin's lymphoma and specific pesticide exposures in men: Cross-Canada study of pesticides and health.** *Cancer Epidemiol Biomarkers Prev* 2001;10(11):1155-63.

Perera FP et al. **Cancer: The big questions to address in coming years.** *Cancer Epidemiol Biomarkers Prev* 2011;20(4):571-3.

Rummel MJ et al. **Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).** *Proc ASH* 2009;Abstract 405.

Salles G et al. **Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial.** *Lancet* 2011;377(9759):42-51.

## DREYLING

Determann O et al. **Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.** *Blood* 2008;111(4):2385-7.

Fowler N et al. **The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a Phase I study.** *Proc ASH* 2010;Abstract 964.

Furman RR et al. **CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 $\delta$ , demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia.** *Proc ASH* 2010;Abstract 55.

Goy A et al. **Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study.** *Ann Oncol* 2009;20(3):520-5.

Hess G et al. **Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.** *J Clin Oncol* 2009;27(23):3822-9.

Hoster E et al. **Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma.** *Proc ASH* 2009;Abstract 880.

Jares P et al. **Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics.** *Nature Reviews Cancer* 2007;7(10):750-62.

Katzenberger T et al. **The Ki67 proliferation index is a quantitative indicator of clinical trial risk in mantle cell lymphoma.** *Blood* 2006;107(8):3407.

Wang M et al. **Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.** *J Clin Oncol* 2009;27(31):5213-8.

Weigert O et al. **A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma — Long-term results of a multicenter observation study.** *Leuk Lymphoma* 2009;50(5):716-22.

## FERRAJOLI

Badoux XC et al. **Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.** *Blood* 2011;118(13):3489-98.

Eichhorst BF et al. **First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.** *Blood* 2009;114(16):3382-91.

Ferrajoli A. **Chronic lymphocytic leukemia: Treatment of younger patients with chronic lymphocytic leukemia.** *Hematology* 2010;82-9.

Foà R et al. **Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): Effect of pre-treatment biological characteristics and gene expression patterns on response to treatment.** *Proc ASH* 2011;Abstract 294.

Hallek M et al. **Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial.** *Lancet* 2010;376(9747):1164-74.

Hillmen P et al. **Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): Final response analysis of an open-label Phase II study.** *Proc ASH* 2010;Abstract 697.

Knauf WU et al. **Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.** *J Clin Oncol* 2009;27(26):4378-84.

Tam CS et al. **Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.** *Blood* 2008;112(4):975-80.

Woyach JA et al. **Impact of age on outcomes following initial therapy with various chemotherapy and chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia (CLL): Results of CALGB studies.** *Proc ASH* 2011;Abstract 289.

## VOSE

Ballester B et al. **Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.** *Oncogene* 2006;25:1560-70.

Bolden JE et al. **Anticancer activities of histone deacetylase inhibitors.** *Nat Rev Drug Discov* 2006;5(9):769-84.

Chen R et al. **Results of a pivotal Phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma.** *Proc ASH* 2010;Abstract 283.

Gallamini A et al. **Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study.** *Blood* 2004;103(7):2474-79.

Kwon HJ et al. **Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.** *Int J Cancer* 2002;97(3):290-6.

O'Connor O et al. **PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).** *Proc ASCO* 2009;Abstract 8561.

Pearl MJ et al. **Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.** *Proc Nat Acad Sci* 2005;102(10):3697-702.

Shustov AR et al. **Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma.** *Proc ASH* 2010;Abstract 961.

Sirotnak FM et al. **A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.** *Cancer Chemother Pharmacol* 1998;42(4):313-8.

Wang ES et al. **Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.** *Leuk Lymphoma* 2003;44(6):1027-35.

Wang Y et al. **FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.** *Biochem Biophys Res Commun* 2007;356(4):998-1003.

## ZINZANI

Al-Tourah AJ et al. **Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.** *J Clin Oncol* 2008;26(32):5165-9.

Bastion Y et al. **Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.** *J Clin Oncol* 1997;15(4):1587-94.

Chim CS et al. **Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.** *Human Pathol* 2007;38(12):1849-57.

Czuczman MS et al. **The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.** *Br J Haematol* 2011;154(4):477-81.

Friedberg JW et al. **Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study.** *J Clin Oncol* 2008;26(2):204-10.

Horning SJ. **Natural history of and therapy for the indolent non-Hodgkin's lymphomas.** *Semin Oncol* 1993;20(5):75-88.

O'Shea D et al. **Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.** *Blood* 2009;113(10):2298-301.

Pennanen H et al. **Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.** *Eur J Haematol* 2008;81(4):289-7.

Rossi D et al. **Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma.** *Haematologica* 2006;91(10):1405-9.